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Introduction: The aim of the present study was to evaluate the effect of a transgenic-induced chronic increase
of Ang-(1–7) on the expression of inﬂammatory markers in adipose tissue and the metabolic proﬁle in rats
treated with high-fat diet.
Research design and methods: Transgenic rats expressing an Ang-(1–7)-producing fusion protein (TGR L-3292)
and Sprague Dawley (SD) control rats 4 weeks oldwere treated for 8 weekswith a high-fat diet. Food intake and
body weight were measured once a week. Glucose-tolerance and insulin sensitivity tests were performed one
week before the sacriﬁce. At the end of the experiment plasma lipid concentrations were measured in TGR
and SD rats. Adipose tissue were weighted and corrected by the body weight. Proinﬂammatory markers in
adipose tissue were analyzed using Western-blotting, real time-PCR and immunohistochemistry.
Results: High-fat diet TGR rats presented increased HDL cholesterol levels and decreased abdominal fat mass,
without changes in food intake. In addition, rats with increased Ang-(1–7) levels had lower body weight.
Molecular analysis revealed decreased IL-1β and COX-2 in adipose tissue.
Conclusions: Taken together, these results show that chronic high circulating angiotensin-(1–7) levels protect
against metabolic stress induced by a high-fat diet decreasing the proinﬂammatory proﬁle of adipose tissue.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The prevalence of obesity is markedly rising in the world [1,2] and
is of considerable concern given the strong association between
obesity, dietary fat intake and cardiometabolic diseases [3,4]. Obesity
is characterized by the accumulation of body fat. The body can adjust
the mix of metabolic fuels it oxidizes so that alcohol, carbohydrate,
and protein intakes are tightly regulated [4,5]. In fact, the body can
achieve carbohydrate and protein balances quickly. However, the
body has a poor autoregulatory system for fat and an almost unlimited
ability to store it [4]. Ultimately, obesity is caused by a positive energy
balance and presently dietary fat intake is considered an important con-
tributor to energy balance [4]. In addition, several authors considero, Departamento de Fisiologia
Av Antonio Carlos 6627-ICB,
3499 2924/2956.
Santos),
de Farmacologia UFMG/Belo
vier OA license.obesity as a local and systemic inﬂammatory state associated with fat
tissue over-production of many cytokines [6,7].
Adipose tissue is a complex population of cells that modulate not
only adipose tissue biology, but also insulin sensitivity, the reproductive
and endocrine systems, immunity, and inﬂammation [6]. There are
several evidences suggesting that inﬂammation plays a major role in
the initiation and maintenance of obesity through adipogenesis
[2,6–10]. White adipose tissue (WAT) becomes inﬂamed during adi-
pose tissue hypertrophy due to inﬁltration bymacrophages that secrete
proinﬂammatory cytokines, including tumor necrosis factor TNF-α and
IL-1β [11]. Another important enzyme involved in the production of
several inﬂammatory mediators is cyclooxygenase 2 (COX2), which
participates in obesity-related disturbances [12,13].
There is an increasing body of evidence showing the involvement
of the renin-angiotensin (ANG) system (RAS) in inﬂammatory dis-
eases [14–16]. Indeed, inﬂammatory cells have several components
of the RAS [15], which are upregulated in some diseases such as rheu-
matoid arthritis [16,17].
The RAS is classically described as an important modulator of
blood pressure and hydroelectrolytic balance. More recent studies
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[18,19]. Results from experimental animals and humans suggest
that obesity activates the RAS arm composed of ACE/Ang II/AT1
[19,20]. It is well known that adipose tissue expresses all components
of the RAS and is markedly involved in obesity in which augmented
expression of angiotensinogen and increased tissue and circulating
levels of Ang II are observed [19]. On the other hand, recent studies
indicate that the counterregulatory arm of RAS composed of the
ACE2/Ang-(1–7)/Mas axis is able to produce an improvement in
lipid and glucose metabolism decreasing body fat [21–24]. The ﬁrst
study correlating Ang-(1–7) with metabolism showed that Mas re-
ceptor deﬁciency in FVB/N mice presented a metabolic state similar
to the metabolic syndrome with dyslipidemia, hypertension, lower
glucose tolerance and insulin sensitivity, hyperinsulinemia, hyper-
leptinemia, decreased glucose uptake in white adipose cells, and an
increased adipose tissue mass [22]. A more recent study showed
that transgenic rats with increased plasma Ang-(1–7) caused by over-
expression of an Ang-(1–7)‐producing fusion protein presented
enhanced glucose tolerance, insulin sensitivity, and insulin-stimulated
glucose uptake [25]. In addition, these transgenic rats presented de-
creased triglycerides and cholesterol levels, as well as a signiﬁcant de-
crease in abdominal fat mass associated with augmented adiponectin
production [25].
In the present study, we sought to evaluate the expression of
pro-inﬂammatory markers in adipose tissue and the metabolic proﬁle
in transgenic rats (TGR) presenting a signiﬁcant increase in Ang-(1–7)
plasma levels treated with high-fat diet. We used the model TGR(A1–
7)3292 (TGR),which expresses anAng-(1–7)‐producing fusion protein,
that results in a chronic elevation of circulating Ang-(1–7) levels
[25,26].
2. Material and methods
2.1. Animals
Ten to twelve week-old male TGR and control Sprague Dawley
(SD) rats were obtained from the transgenic animal facilities of the
Laboratory of Hypertension, Federal University of Minas Gerais, Belo
Horizonte, Brazil. All experimental protocols were performed in
accordance with the international guidelines for animal care and
approved by local authorities. The animals were maintained under
controlled light and temperature conditions, and had free access to
water and chow diet.
2.2. High-fat hypercaloric diet preparation
The high-fat diet was prepared according to the standards of the
Association of Ofﬁcial Analytical Chemists used as described previ-
ously [27,28]. Diet macronutrients were weighed and mixed homoge-
neously to form a soft dough. The diet was stored separately in a
refrigerator (4 °C) in hermetically sealed plastic boxes. The standard
diet (Purina–Labina®) used for the regular maintenance of our rats
is composed of 50.30% carbohydrates, 41.90% protein and 7.80% fat
presenting a total of 2.18 kcal per 1 g of the diet. The high-fat diet
was composed of 24.55% carbohydrates, 14.47% protein and 60.98%
fat, presenting a total of 5.28 kcal per 1 g of the diet. All the high-fat
diet components were purchased from Rhoster® LTDA (São Paulo
SP; Brazil).
2.3. Measurements of body weight, food intake and tissue collection
The rats were individually housed and the food intake was mea-
sured every other week, during two consecutive days in order to ob-
tain food efﬁciency (food intake/body weight).
Overnight fasted rats were killed by decapitation and samples of
blood, epididymal and retroperitoneal white adipose tissues werecollected, weighed and immediately frozen in dry ice and stored at
−80 °C for posterior analysis.
2.4. Determination of blood parameters
Serum was obtained after centrifugation (3200 rpm for 10 min at
4 °C). Total serum cholesterol and triglycerides were assayed using
enzymatic kits (Doles®, Goias, Brazil). ELISA kits were used to mea-
sure serum adiponectin (AdipoGen®, Seoul, Korea), leptin (R&D
systems®, Minneapolis, USA), and insulin (Linco Research Inc.®,
USA) serum levels. Leptin and adiponectin secretion was calculated
as serum levels normalized to fat tissue weight.
2.5. Glucose tolerance and insulin sensitivity tests
For the glucose-tolerance test, D-glucose (2 mg/g of body weight)
was intraperitoneally injected into overnight fasted rats. Glucose
levels from tail blood samples were monitored at 0, 15, 30, 60 and
120 min after injection using an Accu-Check glucometer (Roche
Diagnostics Corp.®, Indianapolis, Indiana, USA). Insulin sensitivity
test was performed on overnight fasted rats, after intraperitoneal in-
jection of insulin (0.75 U/kg body weight—Sigma®, St Louis, MO,
USA). Tail-blood samples were taken at time points 0, 15, 30 and
60 min after injection for the measurement of blood glucose levels.
2.6. Western blotting analysis
Proteins were extracted from epididymal adipose tissue samples
(~300 mg) of TGR and SD rats and 30 μg of protein were resolved
on SDS-PAGE gels (10%), transferred onto nitrocellulose membranes
and blocked with 5% pure milk diluted in 1× TBS. The blot was probed
with COX2 enzyme antibody (Cell Signaling, USA; 1:1000), diluted in
1× blocking buffer, washed in 1× TBS with 1% of Tween 20, and then
incubated with either IRDye 800 anti-goat secondary antibody
(Rockland Immunochemicals®, Gilbertsville, Pa.) diluted to 1:10,000
in blocking buffer followed by further washes with PBS-Tween 20
and one wash in TBS. The blots were viewed using an infrared scanner
from LICOR and analyzed using the Odyssey software.
2.7. Reverse transcription and real time PCR
The total RNA from the adipose tissues was prepared using the
TRIzol reagent (Invitrogen Corp.®, San Diego, California, USA), treated
with DNAse and reverse transcribed with M-MLV (Invitrogen Corp.®)
using random hexamer primers. The levels of TNF-α, IL-1β mRNA
were determined by real-time PCR using SYBR Green reagent
(Appllied Biosystems®—USA) in an ABI Prism 7000 platform (Appllied
Biosystems) with primers TNF-α‐FW: 5′-TGC CTC AGC CTC TTC TCA
TT-3′, and TNF-α–RV: 5′-CCC ATT TGG GAA CTT CTC CT-3′ and
IL-1β-FW: 5′ATG GCA ACT GTC CCT GAA CTC ACC T‐3′ and
IL-1β-RV: 5′CAG GAC AGG TAT AGA TTC AAC CCC T‐3′. Gene expres-
sionwas normalized to the endogenous glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) FW: 5′‐AAC GAC CCC TTC ATT GAC CTC and
RV: 5′-CTT CCC ATT CTC AGC CTT GAC T. The relative comparative CT
method of Livak and Schmittgen was applied to compare gene ex-
pression levels between groups, using the equation 2−ΔΔCT [29].
2.8. Hematoxylin and eosin staining
Epididymal fat tissues fromTGRand SD ratswereﬁxed in Bouin's so-
lution and embedded in parafﬁn serially sectioned at 5 μm, stainedwith
hematoxylin and eosin (HE), and evaluated under a conventional light
microscope using an Olympus BX50microscope (Tokyo, Japan). Images
of fat tissue areas (×10 ocular and ×40 objective lenses) were captured
with Evolution LC Color light camera (MediaCybernetics®, USA). A total
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measured using the NIS-ELEMENTS BR 2.30 Software (ESTADO, USA®).
2.9. Immunohistochemical reactions
For immunohistochemical reactions, 3 μm-thick sections were
mounted on organosilane‐coated slides. The primary mouse monoclo-
nal antibodies against anti‐IL1-β (clone H-153, ABCAM®, Cambridge,
UK) and TNF-α (clone ab66579, ABCAM®, Cambridge, UK) cytokines
were detected with the aid of an LSAB™ kit (product # K0690;
Dako®, Glostrup, Denmark) employing chromogen diaminobenzidine
for color development. Slides were ﬁnally counterstained with Mayer's
hematoxylin and were mounted. Negative controls were obtained by
substituting normal whole rabbit serum (product # X0902; Dako) for
the primary antibodies. Positive controls were applied according to
manufacturer's instructions. Only cells that presented brown cytoplasm
staining were considered positive.
2.10. Statistical analysis
All data were transferred to the GraphPad Prism software (Version
4.0®; San Diego, California, USA) and submitted to speciﬁc tests
with a statistic conﬁdence of 95% (pb0.05). Data are expressed asFig. 1. Body weight, fat weight, adipocyte area and hematoxylin/eosin staining in TGR, SD, TG
(A), epididymal adipose tissue weight (B), retroperitoneal adipose tissue weight (C), adipocy
(F). Curves in A are signiﬁcantly different. * pb0.05 between SD and TGR; & pb0.05 betwe
TGRstd. The two-way ANOVA test was used in A, B and C.the mean±SEM. The statistical signiﬁcance of the differences in
mean values between TGR and SD rats groups were assessed with
the unpaired Student's t-test or two-way ANOVA (body weight, glu-
cose tolerance and insulin sensibility tests).
3. Results
3.1. Body composition and food intake
As shown in Fig. 1 the body weight of TGR rats (N=7) was lower
than that of SD control rats (N=7) during the period of the
hyperlipidic diet treatment. At the end of the experiment the body
weight was 418.3±19.78 g and 355.8±12.34 g in SD and TGR respec-
tively. Analysis of epididymal adipose tissue (0.01895±0.00153 g/g
BW in SD vs 0.01303±0.000848 g/g BW in TGR) and retroperitoneal
adipose tissue (0.02024±0.00133 g/g BW in SD vs 0.01305±
0.00146 g/g BW in TGR) demonstrated a reduced fat composition in
TGR (Fig. 1). Despite of a decreased fatmass, adipocyte areawas not sig-
niﬁcantly diminished in TGR as demonstrated by the morphometrical
assessment of the adipose tissue (Fig. 1).
In order to conﬁrm obesity induced by the high-fat diet we mea-
sured the body weight and adipose tissue weight of transgenic rats
(TGRstd) and the Sprague Dawley rats (SDstd) treated with standardR standard chow (TGRstd) and SD standard chow (SDstd) rats. Body weight over weeks
te area (D), SD hematoxylin and eosin staining (E), TGR hematoxylin and eosin staining
en SD and SDstd; # pb0.05 between TGR and TGRstd; + pb0.05 between SDstd and
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TGRstd and SDstd when compared with those of high-fat fed animals
as showed in Fig. 1.
Every other week, food efﬁciency (food intake corrected by body
weight), was measured and no signiﬁcant alteration in food con-
sumption was observed as shown in the table. The measurement
was performed during two consecutive days and the result represents
the average value for food consumption of the entire treatment
period.3.2. Lipid and glycemic parameters
Two weeks before the sacriﬁce, SD and TG presented similar insu-
lin sensitivity and glucose tolerance (Fig. 2). Total cholesterol, HDL
cholesterol and triglycerides were measured in serum after sacriﬁce.
We observed a signiﬁcant increase in HDL cholesterol (40.55±
2.58 mg/dl in SD vs 55.49±3.16 mg/dl in TGR rats) without alter-
ations in the other plasma lipids (Fig. 2).3.3. Adipokines and insulin circulating levels
As shown in Table 1 serum circulating levels of insulin, adiponectin
and leptin in TGR were similar to those of SD rats.Fig. 2. Lipid and glycemic proﬁle in TGR and SD rats. Insulin sensitivity test (A), glucose toleran
(E). Data are presented as mean±SEM; * pb0.05.3.4. Inﬂammatory markers in adipose tissue
Epididymal adipose tissue was used to perform Western blot for
COX2 and to determine the gene expression of proinﬂammatory cyto-
kines. The results demonstrated a signiﬁcant decrease in COX2 levels
in the fat tissue of TGR (0.08741±0.01877 AU) compared with that
of the SD (0.2541±0.0578 AU). An important reduction in IL-1β
was also observed (1.07±0.188 AU in SD vs 0.472±0.109 AU in
TGR). TNF-α expression was similar in both groups (1.226±
0.397 AU in SD vs 1.948±0.511 AU in TGR). Immunohistochemistry
analysis of adipose tissue illustrated the IL-1β and TNF-α results
(Fig. 3).
4. Discussion
In this study we took advantage of TGR-L3292 rats, which present
elevated levels of circulating Ang-(1–7) in order to further address
the metabolic role of this heptapeptide. The response to high-fat
diet of SD and TGR rats was evaluated. The main differences observed
in the TGR rats in comparison with the SD rats were: decreased body
weight and adipose tissue mass associated with increased circulating
HDL cholesterol and diminished pro-inﬂammatory markers in adi-
pose tissue.
Despite an unchanged food intake and adipocyte diameter, TGR
animals exhibited an important reduction in abdominal fat mass asce test (B), plasma total cholesterol (C), plasma HDL cholesterol (D), plasma triglycerides
Table 1
Food intake, adipokines and insulin in fasted SD and TGR rats.
Measurements SD TGR
Food intake (g/kg BW/day) 52.38±3.66 57.06±3.04
Leptin (pg/ml) 1.359±0.272 1.046±0.323
Adiponectin (ng/ml) 16,437±652 14,430±750
Insulin (ng/ml) 0.950±0.131 1.014±0.126
Data are expressed as mean±SEM.
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tissue) and decreased body weight gain. The absence of alterations in
food intake indicates that the difference in fat mass was not induced
by decreased appetite and probably it was due to changes in metabolic
regulation. These results point out to a decrease in adipocyte cellFig. 3. Adipose tissue inﬂammatory markers. Western blot for COX2-epididymal adipose ti
chemical reaction for IL-1β in epididymal adipose tissue (C), TGR immunohistochemica
epididymal adipose tissue (E), SD immunohistochemical reaction for TNF-α in epididymal a
tissue (G). Data are presented as mean±SEM; * pb0.05.proliferation, which is commonly induced by a high-fat diet, justifying
the lower fat mass. Jayasooriya et al. [30] reported that a mouse lacking
the ACE gene presented increased energy expenditure with reduced fat
mass associated with increased Ang-(1–7) plasma levels [30]. Corrobo-
rating these ﬁndings, it was demonstrated that FVB/N mice with the
deletion of the Ang-(1–7), Mas, receptor presented increased body fat
withmetabolic disturbance [22,31]. These observations suggest a pivot-
al role of the RAS in fat mass control.
Recently it has been demonstrated that, at basal state, TGR rats
present improved glycemic and lipid proﬁles [25]. However, in the
previous study it was not evaluated whether this proﬁle could be al-
tered under metabolic stress or in a metabolic disease state. In the
present study, we observed an important decrease in both adipose
tissue mass and body weight despite of the high-fat diet feeding, in
these rats. Nevertheless, the insulin sensitivity and glucose tolerancessue (A), RT-PCR expression of IL-1β‐epididymal adipose tissue (B), SD immunohisto-
l reaction for IL-1β in epididymal adipose tissue (D), RT-PCR expression of TNF-α‐
dipose tissue (F), TGR immunohistochemical reaction for TNF-α in epididymal adipose
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improved in TGR rats when compared with those in SD control rats.
The prevention of body weight and adiposity gain point to a potential
regulatory role of Ang-(1–7) in metabolism. However, the beneﬁcial
effects can be attenuated by a continuous deleterious metabolic stim-
ulus (high-fat diet) as evidenced by the non‐altered insulin sensitivi-
ty and glucose tolerance in TGR. Previous studies have demonstrated
the prejudicial effects of high-fat diet on metabolic performance
[32–34], which corroborate our results.
Several studies reported that TNF-α and IL-1β are increased in obe-
sity and this increase is correlated with numerous metabolic disorders
[35]. In patients with obesity, adipose tissue is characterized by low-
intensity inﬂammation and increased secretion of cytokines [8,35,36].
Tumor necrosis factor α (TNF-α), interleukin-6 and interleukin-1 β
may be themost pernicious, since they alter adipose tissue function, in-
ﬂuence adipogenesis, and are involved in the metabolic complications
of obesity [8,36]. A recent work by da Silveira et al. [16] demonstrated
that the activation of the Ang-(1–7) Mas receptor exerts signiﬁcant
anti-inﬂammatory effects in two models of arthritis. Overall, genetic
deletion of the receptor was associated with slight worsening of some
aspects of arthritis in mice [16]. A mechanism that can partially explain
this decreased pro-inﬂammatory proﬁle is the regulation of the
PPAR-gamma receptor by the Ang-(1–7)/Mas axis as described recently
by Mario et.al usingMas-knokcoutmice [31].
IL-1β, a cytokine mainly produced by macrophages, endothelial
cells, lymphocytes and epidermal cells, plays a role in the immune re-
sponse and in inﬂammatory process, including obesity [37,38]. IL-1β,
IL6 and TNF-α [6,39] are also produced by adipocytes and pre-
adipocytes especially in unbalanced metabolic states [40,41]. Circulat-
ing levels of IL-1β are correlated with the BMI of obese alcoholic
subjects [42] and are increased in overweight and obese subjects
compared with lean subjects [43]. In adipose tissue from obese sub-
jects, the total release of IL1B was comparable with that of TNF-α
[44]. The IL1 receptor is also overexpressed in the adipose tissue of
mice with diet-induced and genetic obesity, as it is also in the subcu-
taneous adipose tissue of obese patients [45,46]. All these ﬁndings
support the hypothesis that IL1 signaling pathways, more speciﬁcally
IL1B signaling in adipose tissue, may play an important role in
obesity-linked insulin resistance. Silveira et al. showed in a mice
model of arthritis that treatment with Mas receptor agonist, AVE, in-
duced the decreased expression of IL-1β [16]. Accordingly, our results
demonstrated an important decrease in IL-1B expression in adipose
tissue of TGR animals pointing to an anti-inﬂammatory and anti‐
obesogenic effect of Ang-(1–7). It remains to be determined whether
this effect is due to an action of the peptide in adipocytes, in macro-
phages [47] or both. In addition, further studies are necessary to clar-
ify the absence of changes in TNF-α expression in the TGR rats treated
with a high-fat diet. One possibility to be tested in future studies is
that plasma levels of Ang-(1–7) in our TGR (2–2.5‐fold increase
over the normal levels) may not be high enough to change TNF-α
production in this metabolic condition.
Concerning the mechanisms involved in the prevention of a
proinﬂammatory proﬁle and the improvement of metabolism in
TGR rats, despite the deleterious stimulus of high-fat diet, we hypoth-
esize that decreased proinﬂammatory proteins in adipose tissue in-
duced by Ang-(1–7) is able to improve metabolism. A recent study
demonstrated that the IL-1 receptor is a key mediator of high-fat
diet induced inﬂammation in adipose tissue and the deletion of the
IL-1 receptor can partially protect against obesity-induced metabolic
dysregulation in mice [48]. A similar mechanism can partially protect
TGR rats against metabolic dysregulation.
A recent study suggested that cyclooxygenase (COX) 2-mediated
inﬂammation in fat may be crucially involved in obesity-related insu-
lin resistance and fatty liver in high-fat-fed rats, increasing oxidative
stress [12]. Accordingly, Hsieh et al. demonstrated that inhibition of
COX2 activation in high fat-induced obese rats leads to attenuationof adipose inﬂammation in both visceral and subcutaneous fat [13].
The present results demonstrated that increased circulating Ang-(1–7)
is able to decrease the expression of COX-2 in adipose tissue of
high-fat treated rats. Therefore, at least two pro-inﬂammatory mecha-
nisms activated by high fat diet, increase in IL1B and COX-2, were atten-
uated in TGR.
A limitation of the present study was not to have evaluated the di-
rect effect of high-fat diet on plasma Ang-(1–7) levels. However, our
main focus was to evaluate the ability of increased circulating
Ang-(1–7), at the beginning of the diet treatment, to prevent WAT in-
ﬂammation. In future studies it would be important to test the effect
of different diet compositions on the RAS balance and whether treat-
ment with Ang-(1–7) could revert the pro-inﬂamatory changes in-
duced by a high fat diet.
5. Conclusions
In conclusion, this study shows that increased circulating Ang-(1–7)
at the beginning of the diet treatment presents a protective effect
against the proinﬂammatory proﬁle in the adipose tissue of an over-
weight rat model induced by a high-fat diet. TGR animals presented de-
creased body weight, increased HDL cholesterol and decreased
expression of COX-2 and IL-1β in abdominal fat. These results support
the putative use of Ang-(1–7) as a novel therapeutic agent for the pre-
vention and treatment of obesity-related disorders.
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